OTCPK:DSRL.F

Stock Analysis Report

Executive Summary

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide.

Snowflake

Fundamentals

Excellent balance sheet with proven track record and pays a dividend.


Similar Companies

Share Price & News

How has DiaSorin's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

DSRL.F

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

DSRL.F

9.7%

US Medical Equipment

0.7%

US Market

No trading data on DSRL.F.

No trading data on DSRL.F.


Share holder returns

DSRL.FIndustryMarket
7 Day0%1.2%-0.6%
30 Day-2.7%3.5%4.9%
90 Dayn/a3.2%1.7%
1 Yearn/a10.6%9.7%3.0%0.7%
3 Year78.4%78.4%70.6%65.4%44.8%35.4%
5 Year189.7%189.7%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is DiaSorin's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is DiaSorin undervalued based on future cash flows and its price relative to the stock market?

35.69x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

DiaSorin's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

DiaSorin's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

DiaSorin is good value based on earnings compared to the US Medical Equipment industry average.

DiaSorin is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

DiaSorin is poor value based on expected growth next year.


Price Based on Value of Assets

DiaSorin is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is DiaSorin expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

8.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

DiaSorin's revenue is expected to grow by 7.5% yearly, however this is not considered high growth (20% yearly).

DiaSorin's earnings are expected to grow by 8% yearly, however this is not considered high growth (20% yearly).

DiaSorin's revenue growth is expected to exceed the United States of America market average.

DiaSorin's earnings growth is positive but not above the United States of America market average.

DiaSorin's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

DiaSorin is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has DiaSorin performed over the past 5 years?

15.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

DiaSorin's year on year earnings growth rate has been positive over the past 5 years.

DiaSorin's 1-year earnings growth is less than its 5-year average (4.6% vs 15.2%)

DiaSorin's earnings growth has not exceeded the US Medical Equipment industry average in the past year (4.6% vs 28.2%).


Return on Equity

DiaSorin has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

DiaSorin used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

DiaSorin has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is DiaSorin's financial position?


Financial Position Analysis

DiaSorin is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

DiaSorin's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

DiaSorin's level of debt (5.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.8% vs 5.7% today).

Debt is well covered by operating cash flow (506.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 135.5x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 10.9x debt.


Next Steps

Dividend

What is DiaSorin's current dividend yield, its reliability and sustainability?

1.14%

Expected Dividend Yield


Dividend Yield and Payments Analysis

DiaSorin's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

DiaSorin's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (3.3x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.8x coverage).


Next Steps

Management

What is the CEO of DiaSorin's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average management tenure


CEO

Carlo Rosa (53yo)

13.7yrs

Tenure

€1,330,000

Compensation

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa l ...


CEO Compensation Analysis

Carlo's remuneration is lower than average for companies of similar size in United States of America.

Carlo's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.7yrs

Average Tenure

54.5yo

Average Age

The tenure for the DiaSorin management team is about average.


Board Age and Tenure

7.9yrs

Average Tenure

59.5yo

Average Age

The tenure for the DiaSorin board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Carlo Rosa (53yo)

    CEO, GM & Executive Director

    • Tenure: 13.7yrs
    • Compensation: €1.33m
  • Chen Even (56yo)

    Chief Commercial Officer

    • Tenure: 12.5yrs
    • Compensation: €663.00k
  • Stefano Ronchi (59yo)

    Senior Corporate Vice President of Human Resources

    • Tenure: 0yrs
  • Riccardo Fava

    Senior Director of Investor Relations & Corporate Communication

    • Tenure: 0yrs
  • Marco Minolfo

    Manager of the Corporate Legal Affairs Department

    • Tenure: 0yrs
  • Piergiorgio Pedron (48yo)

    Corporate Accounting Documents Officer

    • Tenure: 3.3yrs

Board Members

  • Gustavo Denegri (82yo)

    Chairman

    • Tenure: 9.4yrs
    • Compensation: €400.00k
  • Enrico Amo (63yo)

    Non-Executive Director

    • Tenure: 12.5yrs
    • Compensation: €35.00k
  • Michele Denegri (50yo)

    Deputy Chairman

    • Tenure: 6.4yrs
    • Compensation: €150.00k
  • Francesco Moscetti (68yo)

    Independent Director

    • Tenure: 12.5yrs
    • Compensation: €55.00k
  • Carlo Rosa (53yo)

    CEO, GM & Executive Director

    • Tenure: 13.7yrs
    • Compensation: €1.33m
  • Chen Even (56yo)

    Chief Commercial Officer

    • Tenure: 12.5yrs
    • Compensation: €663.00k
  • Giuseppe Alessandria (77yo)

    Lead Independent Director

    • Tenure: 6.4yrs
    • Compensation: €45.00k
  • Roberta Somati (50yo)

    Independent Director

    • Tenure: 6.4yrs
    • Compensation: €35.00k
  • Giancarlo Boschetti (80yo)

    Director

    • Tenure: 3.4yrs
  • Monica Mannino (50yo)

    Chairman of Board of Statutory Auditors

    • Tenure: 3.4yrs

Company Information

DiaSorin S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DiaSorin S.p.A.
  • Ticker: DSRL.F
  • Exchange: OTCPK
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €5.728b
  • Listing Market Cap: €6.302b
  • Shares outstanding: 54.66m
  • Website: https://www.diasoringroup.com

Number of Employees


Location

  • DiaSorin S.p.A.
  • Via Crescentino
  • Saluggia
  • Vercelli
  • 13040
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DIABIT (Borsa Italiana)YesCommon SharesITEURJul 2007
34DDB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2007
DSRL.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJul 2007
0GZXLSE (London Stock Exchange)YesCommon SharesGBEURJul 2007
DIAMBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJul 2007

Biography

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide. The company offers tests for diagnosis in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:29
End of Day Share Price2019/09/09 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.